Harper, Luke
Strandberg, Olof
Spotorno, Nicola
Nilsson, Markus
Lindberg, Olof
Hansson, Oskar
Santillo, Alexander F.
Funding for this research was provided by:
The Schörling foundation
The Swedish federal government ((ALF ST 2021-2023/4-43338), (2022-Projekt0080), (2022-Projekt0080), (ALF 2022 YF 0017))
Knut och Alice Wallenbergs Stiftelse ((2022-0231), (2022-0231))
National Institute of Aging ((R01AG083740), (R01AG083740))
Alzheimer’s Association ((SG-23-1061717), (SG-23-1061717))
Medicinska Forskningsrådet ((ERAPERMED2021-184), (2022-00775))
Swedish Alzheimer Foundation ((AF-980907))
Strategic Research Area MultiPark
the Swedish Brain Foundation ((FO2021-0293))
The Parkinson foundation of Sweden ((1412/22))
the Cure Alzheimer’s fund
The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
The Skåne University Hospital Foundation ((2020-O000028))
Region Skåne ((2022-1259))
Lund University
Article History
Received: 3 January 2024
Accepted: 26 May 2024
First Online: 20 June 2024
Declarations
:
: OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche, and Siemens. All other authors have no financial interests.